The British Pharmacological Society has issued a stark warning about the urgent need for evidence-based guidance on medication use for pregnant women and new mothers. Historically, pregnant and breastfeeding women have been systematically excluded from clinical trials, creating significant and dangerous gaps in safety and efficacy data for essential medicines.
Widespread Medication Use Without Adequate Data
Approximately 80 percent of women in the United Kingdom use at least one medication during pregnancy or while breastfeeding. These women are often forced to make critical healthcare decisions without access to clear, balanced information about the risks and benefits of these treatments.
Current Advice Overemphasises Risks
Existing medical guidance frequently overemphasises the potential risks of medication use during pregnancy and breastfeeding. This approach neglects the substantial harm that can result from leaving maternal conditions untreated, which poses dangers to both the mother and the developing baby.
Call for Inclusive Research and Better Communication
The British Pharmacological Society recommends a comprehensive strategy to address these critical issues. This includes more inclusive research practices that actively involve pregnant and breastfeeding women in clinical trials. Additionally, the society advocates for clearer communication of both risks and benefits associated with medication use during these sensitive periods.
Improved Training for Healthcare Professionals
The organisation also emphasises the need for improved training for healthcare professionals. Better education would enable medical practitioners to provide more nuanced advice and support to pregnant women and new mothers facing medication decisions.
This call to action highlights a fundamental shift needed in pharmacological research and clinical practice to ensure the health and safety of both mothers and their children during pregnancy and the postpartum period.
